当前位置： SCI文献检索 > CANCER GENE THERAPY期刊下所有文献 > Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Abstract：

:CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity. As there are higher T(reg) levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcriptional regulator encoded by the member of the forkhead winged helix protein family (FOXP3) is critical for maintaining the functions of T(reg). We hypothesized that targeting FOXP3 expression with a novel arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino (PPMO) based antisense would eliminate T(reg) and enhance the induction of effector T-cell responses. We observed that the PPMO was taken up by activated T cells in vitro and could downregulate FOXP3 expression, which otherwise increases during antigen-specific T-cell activation. Generation of antigen-specific T cells in response to peptide stimulation was enhanced by pre-treatment of peripheral blood mononuclear cells with the FOXP3-targeted PPMO. In summary, modulation of T(reg) levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Morse MA,Hobeika A,Serra D,Aird K,McKinney M,Aldrich A,Clay T,Mourich D,Lyerly HK,Iversen PL,Devi GR

doi

10.1038/cgt.2011.63

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

30-7

issue

1

eissn

0929-1903

issn

1476-5500

pii

cgt201163

journal_volume

19

pub_type

杂志文章

相关文献

CANCER GENE THERAPY文献大全
  • Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.

    abstract：:The growth of new blood vessels is an essential condition for the development of tumors with a diameter greater than 1-2 mm and also for their metastatic dissemination. RNasin, the placental ribonuclease inhibitor, is known to have antiangiogenic activity through the inhibition of angiogenin and basic fibroblast growt...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700302

    authors： Botella-Estrada R,Malet G,Revert F,Dasí F,Crespo A,Sanmartín O,Guillén C,Aliño SF

    更新日期：2001-04-01 00:00:00

  • Molecular conjugate vectors mediate efficient gene transfer into gastrointestinal epithelial cells.

    abstract：:Transfer of genes to the gastrointestinal epithelium would be advantageous from investigational and therapeutic standpoints. Efficient transfer of DNA to the intestinal epithelial cells, however, has been problematic with conventional viral and nonviral vectors. As an alternative, we have utilized molecular conjugate ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Batra RK,Berschneider H,Curiel DT

    更新日期：1994-09-01 00:00:00

  • Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells.

    abstract：:Doublecortin-like kinase 1 (DCLK1) is a cancer stem cell marker for the colorectal cancer (CRC). It plays critical roles in the oncogenesis, progression, and metastasis of CRC. DCLK1 can be an intriguing therapeutic target for CRC treatment. However, the molecular mechanism of how DCLK1 functions is unclear currently....

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0144-4

    authors： Li L,Mei H,Commey ANA

    更新日期：2020-09-01 00:00:00

  • Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody.

    abstract：:Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700161

    authors： Paul S,Bizouarne N,Dott K,Ruet L,Dufour P,Acres RB,Kieny MP

    更新日期：2000-04-01 00:00:00

  • The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.

    abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2011.68

    authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

    更新日期：2012-01-01 00:00:00

  • Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

    abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.22

    authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

    更新日期：2010-09-01 00:00:00

  • Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.

    abstract：:It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase repo...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700679

    authors： Zhu ZB,Makhija SK,Lu B,Wang M,Kaliberova L,Liu B,Rivera AA,Nettelbeck DM,Mahasreshti PJ,Leath CA,Barker S,Yamaoto M,Li F,Alvarez RD,Curiel DT

    更新日期：2004-04-01 00:00:00

  • Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.

    abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0110-1

    authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

    更新日期：2020-05-01 00:00:00

  • In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system.

    abstract：:We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cel...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700021

    authors： Pitzer C,Schindowski K,Pomer S,Wirth T,Zöller M

    更新日期：1999-03-01 00:00:00

  • Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas.

    abstract：:The targeted expression of transgenes is one of the principal goals of gene therapy, and it is particularly relevant for the treatment of brain tumors. In this study, we examined the effect of the overexpression of human gas1 (growth arrest specific 1) and human p53 cDNAs, both under the transcriptional control of a p...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7701076

    authors： Benítez JA,Arregui L,Vergara P,Segovia J

    更新日期：2007-10-01 00:00:00

  • Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.

    abstract：:Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular recept...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-018-0037-y

    authors： Kubo S,Takagi-Kimura M,Kasahara N

    更新日期：2019-02-01 00:00:00

  • MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis.

    abstract：:Inflammation, among environmental risk factors, is one of the most important contributors to colorectal cancer (CRC) development. In this way, studies revealed that the incidence of CRC in inflammatory bowel disease patients is up to 60% higher than the general population. MicroRNAs (miRNAs), small noncoding RNA molec...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-020-0172-0

    authors： Karimzadeh MR,Zarin M,Ehtesham N,Khosravi S,Soosanabadi M,Mosallaei M,Pourdavoud P

    更新日期：2020-11-01 00:00:00

  • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

    abstract：:Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-020-0174-y

    authors： Choucair K,Morand S,Stanbery L,Edelman G,Dworkin L,Nemunaitis J

    更新日期：2020-12-01 00:00:00

  • Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

    abstract：:The highly metastatic ESb tumor is totally resistant to murine interferon-alpha/beta (IFN-alpha/beta) therapy, regardless of the number of cells injected or the route of inoculation. In contrast, as we show herein, mouse IFN-alpha1-transduced ESb tumor cells were inhibited markedly when injected subcutaneously into im...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700051

    authors： Rozera C,Mecchia M,Gresser I,Bandu MT,Proietti E,Venditti M,Sestili P,Santini SM,Fais S,Belardelli F,Ferrantini M

    更新日期：1999-05-01 00:00:00

  • Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.

    abstract：:Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers. Although the cure rate for sarcomas in general has significantly improved in the last 10 years, there continue to be subgroups that are difficult to treat. High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700798

    authors： Ganjavi H,Gee M,Narendran A,Freedman MH,Malkin D

    更新日期：2005-04-01 00:00:00

  • Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Cancer gene therapy

    pub_type： 已发布勘误

    doi：10.1038/s41417-020-0166-y

    authors： Ballesteros ARR,Hernández R,Perazzoli G,Cabeza L,Melguizo C,Vélez C,Prados J

    更新日期：2020-06-01 00:00:00

  • Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.

    abstract：:The gene transfer of tumor-specific chimeric immunoglobulin T-cell receptors (cIgTCRs) combining antibody-like specificity with the effector cell function could be an attractive tool in immunotherapy. In this study, we directed the human natural killer (NK) cell line YT to tumor cells by gene transfer of a cIgTCR with...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700453

    authors： Schirrmann T,Pecher G

    更新日期：2002-04-01 00:00:00

  • Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model.

    abstract：:The prognosis of glioblastoma remains poor despite intensive research efforts. Glioblastoma stem cells (GSCs) contribute to tumorigenesis, invasive capacity, and therapy resistance. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), a stem cell marker, is involved in the maintenance of GSCs, although ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-00282-5

    authors： Tanigawa S,Fujita M,Moyama C,Ando S,Ii H,Kojima Y,Fujishita T,Aoki M,Takeuchi H,Yamanaka T,Takahashi Y,Hashimoto N,Nakata S

    更新日期：2021-01-07 00:00:00

  • Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways.

    abstract：:In this study, we have applied high-density oligonucleotide microarray technology to characterize biologic changes associated with adenoviral vector-mediated target cell infection. We infected a human melanoma cell line, M21, with the tropism-modified vectors, Ad5lucRGD and Ad5/3luc1. In addition, we infected the M21 ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700776

    authors： Volk AL,Rivera AA,Page GP,Salazar-Gonzalez JF,Nettelbeck DM,Matthews QL,Curiel DT

    更新日期：2005-02-01 00:00:00

  • Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.

    abstract：:Breast cancer is the most common cause of cancer-related death worldwide, thus remaining a crucial health problem among women despite advances in conventional therapy. Therefore, new alternative strategies are needed for effective diagnosis and treatment. One approach is the use of oncolytic viruses for gene-directed ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.49

    authors： Seubert CM,Stritzker J,Hess M,Donat U,Sturm JB,Chen N,von Hof JM,Krewer B,Tietze LF,Gentschev I,Szalay AA

    更新日期：2011-01-01 00:00:00

  • Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.

    abstract：:The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2008.75

    authors： Piao Y,Jiang H,Alemany R,Krasnykh V,Marini FC,Xu J,Alonso MM,Conrad CA,Aldape KD,Gomez-Manzano C,Fueyo J

    更新日期：2009-03-01 00:00:00

  • Targeting gene expression to tumor cells with loss of wild-type p53 function.

    abstract：:The tumor suppressor protein p53 is a transcription factor that can positively regulate the expression of critical target genes involved in negative control of cell growth or induction of apoptosis; p53 is also able to suppress the transcription of other genes by virtue of its ability to bind components of the basal t...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700091

    authors： Zhu J,Gao B,Zhao J,Balmain A

    更新日期：2000-01-01 00:00:00

  • Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase.

    abstract：:A recombinant adenovirus expressing Escherichia coli cytosine deaminase (AdCD) was constructed with the purpose of exploring its utility for the treatment of breast cancer. Infection of the human breast cancer cell line, MDA-MB-231, with AdCD resulted in high levels of cytosine deaminase enzyme activity. MDA-MB-231 ce...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Li Z,Shanmugam N,Katayose D,Huber B,Srivastava S,Cowan K,Seth P

    更新日期：1997-03-01 00:00:00

  • Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect.

    abstract：:Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrat...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2008.20

    authors： Peled M,Shaish A,Greenberger S,Katav A,Hodish I,Ben-Shushan D,Barshack I,Mendel I,Frishman L,Tal R,Bangio L,Breitbart E,Harats D

    更新日期：2008-08-01 00:00:00

  • The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.

    abstract：:Oncolytic viruses (OVs) have shown great anti-cancer potential in animal models, but only modest success in early clinical trials. A better understanding of the mechanisms underlining OV efficacy is needed to resolve this discrepancy. In the clinic, OV therapy will likely be combined with traditional chemotherapy, und...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.33

    authors： Granot T,Meruelo D

    更新日期：2012-08-01 00:00:00

  • Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.

    abstract：:Vesicular stomatitis virus (VSV) is being developed for cancer therapy. We created a recombinant replicating VSV (rrVSV) that preferentially infected Her2/neu expressing breast cancer cells. We now used this rrVSV to treat macroscopic peritoneal tumor implants of a mouse mammary tumor cell line stably transfected to e...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2008.55

    authors： Gao Y,Whitaker-Dowling P,Griffin JA,Barmada MA,Bergman I

    更新日期：2009-01-01 00:00:00

  • Role of autophagy in oncolytic herpes simplex virus type 1-induced cell death in squamous cell carcinoma cells.

    abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2017.33

    authors： Furukawa Y,Takasu A,Yura Y

    更新日期：2017-09-01 00:00:00

  • Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells.

    abstract：:A nonviral gene delivery vector has been developed in our laboratory based on the cationic polymer, poly(2-(dimethylethylamino)ethyl methacrylate) (p(DMAEMA)). p(DMAEMA)-based polyplexes have been successfully used for the transfection of OVCAR-3 cells in vitro. However, these polyplexes were unable to transfect OVCAR...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700311

    authors： Mastrobattista E,Kapel RH,Eggenhuisen MH,Roholl PJ,Crommelin DJ,Hennink WE,Storm G

    更新日期：2001-06-01 00:00:00

  • Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.

    abstract：:Delivery of the full-length tumor antigen might be more successful in immunotherapy than single peptides and has the advantage that patients no longer need to be selected for their HLA type. In this study, we tested the in vitro induction of CAMEL/NY-ESO-ORF2-specific T cells by dendritic cells infected with an adenov...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700674

    authors： Slager EH,van der Minne CE,Goudsmit J,van Oers JM,Kostense S,Havenga MJ,Osanto S,Griffioen M

    更新日期：2004-03-01 00:00:00

  • Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor.

    abstract：:Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The alpha v beta 3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700707

    authors： Li J,Ji J,Holmes LM,Burgin KE,Barton LB,Yu X,Wagner TE,Wei Y

    更新日期：2004-05-01 00:00:00